Outcome Objectives
At the conclusion of this activity, learners will be able to:
-
Apply the latest clinical trial evidence for the management of head and neck cancer.
-
Manage well-differentiated thyroid cancers using the latest guidelines from the American Thyroid Association.
-
Utilize surgical or biologic therapies for the management of chronic rhinosinusitis with nasal polyposis.
-
Counsel patients about the association between rhinosinusitis and asthma.
-
Manage chronic cough with pharmaceutical, behavioral, and procedural therapies.
-
Apply the use of new technologies and therapies for the management of dysphagia.
-
Counsel patients and other providers regarding the indications for cochlear implantation in adults.
-
Manage hearing loss in the pediatric population.
Accreditation / Credit Designation Statement
The University of Arizona College of Medicine - Tucson is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The University of Arizona College of Medicine - Tucson designates this live activity for a maximum of 17 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Relevant Financial Relationships Statement
University of Arizona College of Medicine - Tucson Office of Continuing Medical Education adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers or others are required to disclose all financial relationships with ineligible companies (commercial interests). The CME office reviewers have nothing to disclose. All relevant financial relationships have been mitigated prior to the commencement of the activity.
Dr. Carr has disclosed: Consulting Fee-Pfizer (Any division) (Relationship has ended)|Consulting Fee-Apogee Therapeutics (Relationship has ended).
Dr. Chang has disclosed: Grant or research support-Sanofi S.A.
Dr. Julian has disclosed: Membership on Advisory Committees or Review Panels, Board Membership, etc.-Bristol-Myers Squibb Company (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-AstraZeneca (Any division) (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Merck (Any division) (Relationship has ended).
Dr. Luong has disclosed: Advisor-AstraZeneca (Any division) (Relationship has ended)|Advisor-GlaxoSmithKline (Relationship has ended)|Advisor-Regeneron Pharmaceuticals, Inc. (Relationship has ended)|Advisor-Sanofi S.A.|Consulting Fee-Lyra Therapeutics|Consulting Fee-Maxwell Biosciences|Consulting Fee-Medtronic (Any division)|Consulting Fee-NeuroENT|Advisor-SoundHealth Systems|Consulting Fee-Stryker (Any division)|Grant or research support-Lyra Therapeutics (Relationship has ended)|Grant or research support-Sanofi S.A.|Grant or research support-NeurENT (Relationship has ended)|Grant or research support-Eli Lily.
Dr. Vambutas has disclosed: Grant or research support-Sobi Pharmaceuticals.
All other individuals in a position to control the content of this CME activity have disclosed that they have no relevant financial relationships with ineligible companies that would constitute a conflict of interest concerning this CME activity.